YOLFTbeta
Transgene SA

Transgene SA

TNG · PA · Healthcare / Biotechnology

0.721EUR-0.01 (-1.23%)

Price History

Full chart

Market Stats

Previous Close0.73
Open0.731
Day Range0.718 – 0.741
52-Week Range0.692 – 1.50
Volume63.63K
Market Cap202.85M
P/E (TTM)0.00
Forward P/E8.47
EPS-0.17
Dividend Yield0.00%
Beta0.69
50-Day Avg0.7857
200-Day Avg0.8057

About

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Alessandro Riva M.D.
  • Employees145
  • Headquarters400, boulevard Gonthier d?Andernach, Illkirch-Graffenstaden, France, 67405, France
  • Websitehttps://www.transgene.com

Leadership

  • Dr. Alessandro Riva M.D.CEO & Chairman of the Board · b. 1960
  • Ms. Lucie LarguierVP & Chief Financial Officer · b. 1984
  • Dr. Simone Silva Steiner Ph.D.Chief Technical Officer · b. 1976
  • Dr. Maurizio CeppiChief Scientific Officer · b. 1972
  • Mr. John Felitti J.D., LLMVP, General Counsel & Corporate Secretary · b. 1970
  • Ms. Christelle SchwoererHuman Resources Director · b. 1992
  • Mr. James Wentworth M.B.A., Ph.D.VP & Chief Business Officer · b. 1980
  • Ms. Emmanuelle Dochy M.D.VP of Medical Affairs & Chief Medical Officer · b. 1976
  • Katell Bidet HuangHead of Translational Medicine
  • Ms. Feriel MarinInterim Chief Quality Officer

Financials

Income Statement

Currency: EUR1997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.71M11.67M4.33M4.72M1.26M2.21M2.50M2.51M5.55M28.02M13.95M11.77M14.11M14.45M3.93M3.85M2.49M1.47M2.35M2.10M1.33M13.30M2.98M9.99M3.13M7.90M6.35M490.00K
Growth (%)-+73.84%-62.93%+9.23%-73.33%+75.08%+13.37%+0.52%+120.60%+405.21%-50.22%-15.66%+19.95%+2.37%-72.81%-2.01%-35.31%-41.16%+60.14%-10.53%-36.40%+895.96%-77.58%+235.22%-68.72%+152.72%-19.58%-92.29%
Cost of Revenue1.38M1.53M------24.16M28.80M32.27M33.03M42.52M53.05M14.90M16.40M15.20M2.64M2.04M8.50M27.34M31.39M27.35M32.88M32.17M29.59M34.28M-
Gross Profit5.33M10.13M4.33M4.72M1.26M2.21M2.50M2.51M-18.61M-780.00K-18.32M-21.26M-28.41M-38.60M-10.97M-12.55M-12.71M-1.17M309.00K-6.40M-26.01M-18.09M-24.36M-22.89M-29.04M-21.69M-27.93M490.00K
Gross Margin79.45%86.86%100.00%100.00%100.00%100.00%100.00%100.00%-335.54%-2.78%-131.36%-180.72%-201.31%-267.22%-279.33%-326.08%-510.44%-79.93%13.17%-304.95%-1948.09%-136.05%-817.34%-229.06%-929.05%-274.53%-439.56%100.00%
Operating Expense19.95M24.01M26.12M29.41M25.58M22.59M24.44M24.18M3.90M6.68M3.63M6.07M6.20M6.23M31.16M28.65M34.22M34.64M22.97M21.64M-33.38M7.37M-372.00K635.00K862.00K8.36M7.73M41.56M
Operating Income-14.62M-13.88M-21.79M-24.69M-24.32M-20.38M-21.94M-21.67M-22.51M-7.46M-21.95M-27.34M-34.60M-44.83M-42.13M-41.20M-46.93M-35.81M-22.66M-28.04M7.37M-25.45M-23.99M-23.52M-29.90M-30.05M-35.66M-41.07M
Operating Margin-217.81%-118.98%-503.91%-522.59%-1930.40%-923.80%-877.09%-861.97%-405.95%-26.62%-157.39%-232.34%-245.22%-310.31%-1072.68%-1070.36%-1884.82%-2444.16%-966.07%-1336.02%551.91%-191.44%-804.86%-235.41%-956.62%-380.34%-561.28%-8381.63%
EBITDA-16.00M-37.06M-19.89M-22.88M-21.27M-19.04M-20.39M-20.25M-20.92M-5.15M-18.29M-25.12M-32.19M-40.16M-39.37M-38.27M-37.41M-34.72M-20.38M-29.50M2.85M-23.73M-14.13M-23.55M-30.33M-28.44M-26.65M-39.77M
EBITDA Margin-238.36%-317.70%-459.77%-484.36%-1688.41%-862.87%-815.23%-805.37%-377.26%-18.37%-131.13%-213.53%-228.12%-278.00%-1002.37%-994.23%-1502.25%-2369.90%-868.88%-1405.62%213.26%-178.45%-473.93%-235.66%-970.15%-360.00%-419.52%-8116.33%
Net Income-11.86M-35.00M-18.22M-22.48M-21.95M-18.41M-20.88M-20.48M-22.03M-5.52M-18.00M-27.35M-34.22M-43.63M-43.20M-42.86M-48.56M-46.37M-25.21M-32.27M8.03M-18.80M-18.45M-20.00M-32.81M-22.33M-33.97M-37.52M
Net Income Margin-176.71%-300.00%-421.36%-475.85%-1741.83%-834.36%-834.67%-814.84%-397.24%-19.70%-129.04%-232.44%-242.48%-301.99%-1099.87%-1113.48%-1950.04%-3165.46%-1074.47%-1537.59%601.20%-141.43%-618.92%-200.18%-1049.58%-282.63%-534.72%-7657.96%
R&D17.93M20.86M21.81M22.52M21.06M19.08M20.26M20.01M------48.68M50.06M49.82M32.14M26.42M30.36M27.35M31.39M27.35M32.88M32.17M29.59M34.28M32.60M
R&D as % of Total Revenue267.12%178.83%504.28%476.78%1671.19%864.82%809.96%795.98%------1239.28%1300.68%2000.96%2193.72%1126.13%1446.36%2048.61%236.05%917.34%329.06%1029.05%374.53%539.56%6652.24%
Interest Expense0170.31K00000036.00K33.00K26.00K12.00K0502.00K639.00K702.00K671.00K554.00K752.00K1.08M1.03M1.44M1.34M464.00K804.00K168.00K1.68M1.69M
Interest Expense % of Total Revenue0.00%1.46%0.00%0.00%0.00%0.00%0.00%0.00%0.65%0.12%0.19%0.10%0.00%3.48%16.27%18.24%26.95%37.82%32.05%51.41%77.23%10.85%44.85%4.64%25.72%2.13%26.46%345.10%

Balance Sheet

Currency: EUR1997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets30.15M84.82M66.89M47.94M86.42M66.88M45.82M25.50M32.60M128.31M126.65M98.66M223.69M193.58M160.46M125.85M140.95M100.87M122.95M100.87M108.54M115.48M85.45M101.84M66.44M45.22M42.17M138.83M
Total Liabilities9.47M11.33M11.41M13.15M12.79M11.67M11.30M11.27M13.63M17.38M32.42M30.10M40.07M52.17M60.89M69.23M69.11M74.32M76.45M72.78M71.84M49.78M35.20M34.63M28.59M29.61M26.97M17.09M
Total Equity20.68M73.49M55.48M34.79M73.63M55.21M34.52M14.23M18.98M110.94M94.22M68.56M183.62M141.42M99.58M56.62M71.84M26.55M46.50M28.09M36.70M65.70M50.25M67.21M37.84M15.61M15.20M121.73M
Cash14.25M65.91M50.24M28.48M71.81M54.49M34.94M14.65M20.32M6.00K22.31M64.69M1.38M1.73M6.14M5.14M3.51M3.29M4.86M1.64M1.89M1.34M5.28M5.91M4.40M15.67M16.67M6.66M
Total Debt4.32M4.09M5.74M6.22M6.25M5.89M5.54M5.06M-----20.89M27.83M35.31M36.21M36.41M45.24M42.17M38.87M16.66M5.28M3.84M2.45M1.35M10.40M2.06M
Net Debt-9.93M-61.82M-44.50M-22.27M-65.56M-48.60M-29.40M-9.59M-20.32M-6.00K-22.31M-64.69M-1.38M19.16M21.70M30.18M32.70M33.12M40.38M40.53M36.99M15.32M6.00K-2.07M-1.95M-14.32M-6.44M-4.60M

Cash Flow

Currency: EUR1997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.77M-33.47M-13.88M-22.27M-15.72M-16.02M-18.21M-19.11M-19.54M-2.07M-23.39M-18.72M-24.93M-44.16M-51.29M-50.19M-54.24M-45.15M-33.59M-35.37M-28.38M-22.41M-28.74M-31.94M-20.30M-34.67M-23.55M-36.74M
Investing Cash Flow-1.93M-2.04M-2.06M-1.85M-1.62M-921.00K-979.00K-695.00K9.10M-2.81M-1.89M-4.08M-7.68M-5.52M-4.58M-4.63M532.00K2.32M-2.07M-362.00K-1.40M-531.00K17.74M16.79M20.27M34.57M-3.21M-105.95M
Financing Cash Flow1.01M87.29M204.00K2.38M60.64M-358.00K-352.00K-482.00K14.15M95.87M661.00K796.00K-30.71M50.03M60.26M53.83M52.06M42.58M37.22M32.52M30.02M22.40M14.94M15.77M-1.48M11.37M26.96M134.38M
Capital Expenditure1.93M1.96M1.92M1.76M1.61M886.00K916.00K682.00K787.00K2.64M1.85M4.23M526.00K3.85M1.95M2.18M2.60M1.53M47.00K462.00K1.40M1.73M852.00K686.00K1.53M2.67M3.07M842.00K
Free Cash Flow-13.70M-35.43M-15.81M-24.03M-17.33M-16.91M-19.13M-19.79M-20.32M-4.71M-25.23M-22.95M-25.45M-48.01M-53.24M-52.37M-56.84M-46.68M-33.63M-35.83M-29.79M-24.14M-29.59M-32.63M-21.84M-37.42M-26.62M-37.58M
FCF to OCF116.41%105.85%113.85%107.92%110.23%105.53%105.03%103.57%104.03%227.21%107.89%122.60%102.11%108.72%103.79%104.35%104.80%103.38%100.14%101.31%104.95%107.72%102.96%102.15%107.56%107.92%113.06%102.29%

Key Statistics & Ratios

Market Cap202.85M
Enterprise Value125.77M
Trailing P/E0.00
Forward P/E8.47
PEG Ratio3.08
Price / Sales36.07
Price / Book1.95
EPS-0.17
Book Value0.418
Revenue (TTM)5.62M
Gross Profit (TTM)-28.27M
EBITDA-33.40M
Profit Margin0.00%
Operating Margin-559.31%
Return on Equity-64.21%
Return on Assets-26.24%
Shares Outstanding278.26M
Shares Float46.60M
Beta0.69
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20141×
0.00Jul 16, 2014

Stock Splits

  • Jun 18, 201940:39
  • Oct 25, 20161381:1352
  • Mar 3, 20141585:1538
  • May 11, 2010969:959